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ciation for Thoracic Surgerydoi:10.1016/j.jtcvs.2005.09.006Objective: We sought to identify predictors of operative mortality, pulmonary
morbidity, and cardiovascular morbidity after lung volume reduction surgery.
Methods: Univariate and multivariate logistic regression analyses were performed.
Candidate predictors included demographic characteristics, physical condition char-
acteristics, pulmonary function measures, measures of the distribution of emphy-
sema as determined by radiologists and by means of computerized analysis of chest
computed tomographic scans, and measures of exercise capacity, dyspnea, and
quality of life. End points analyzed were operative mortality (death within 90 days
of the operation), major pulmonary morbidities (tracheostomy, failure to wean,
reintubation, pneumonia, and ventilator for 3 days), and cardiovascular morbid-
ities (infarction, pulmonary embolus, or arrhythmia requiring treatment).
Results: Five hundred eleven patients in the non–high-risk group of the National
Emphysema Treatment Trial underwent lung volume reduction. The incidence of
operative mortality was 5.5%, major pulmonary morbidity occurred in 29.8% of
patients, and cardiovascular morbidity occurred in 20.0% of patients. Predictors for
these end points are as follows:
Relative odds P value
Operative mortality Non–upper-lobe predominance
(radiologist)
2.99 .009
Pulmonary morbidity Age in years 1.05 .02
FEV1 % predicted 0.97 .05
DLCO % predicted 0.97 .01
Cardiovascular morbidity Age in years 1.07 .004
Oral steroid use 1.72 .04
Non–upper-lobe predominance
(QIA  measure)
2.67 .001
FEV1, Forced expiratory volume in 1 second; DLCO, diffusion capacity; QIA, quantitative image analysis.
Conclusions: Although lung volume reduction can be performed in selected patients
with acceptable mortality, the incidence of major cardiopulmonary morbidity re-
mains high. The lone predictor for operative mortality of lung volume reduction was
the presence of non–upper-lobe-predominant emphysema, as assessed by the radi-
ologist. Pulmonary morbidity can be expected in elderly patients who have a low
diffusing capacity for carbon monoxide and forced expiratory volume in 1 second.
When assessing morbidity, the computer-assisted chest computed tomographic
analysis proved useful only in predicting cardiovascular complications.
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TS Lung volume reduction surgery (LVRS) has beendemonstrated to be beneficial in selected patientswith severe emphysema.1 However, because of the
fragile nature of patients with severe emphysema, surgical
morbidity and mortality remain higher than for most other
elective thoracic surgical procedures. Reported operative
mortalities have ranged from 4% to as high as 14%, whereas
the incidence of pulmonary complications, such as pneu-
monia, reintubation, and ventilator dependence, are also
reported to be higher than that observed for most other
commonly performed thoracic procedures.2,3
Previous studies have proposed several demographic,
pulmonary, and cardiovascular physiologic and/or radio-
graphic features predictive of excessive morbidity in
patients undergoing LVRS.4-9 It was hoped that identifi-
cation of factors that portend high morbidity might lead
to the exclusion of patients from consideration for LVRS,
or alternatively, practitioners might be alerted to specific
risks and take steps to avoid predicted complications.
However, these studies yield conflicting results about
which factors are predictive of morbidity, and uncertainty
still remains regarding the validity of their predictions.
Unfortunately, virtually all of these studies have serious
limitations, including small patient numbers, selection
bias, institutional bias, and incomplete or suboptimal data
collection.
The National Emphysema Treatment Trial (NETT), a
large, prospective, randomized, multicenter, long-term trial
comparing optimum medical therapy with optimum therapy
plus LVRS was conceived and designed to provide more
definitive answers regarding not only the value of LVRS but
also optimal patient selection. A prior NETT publication
sought to establish the efficacy of LVRS and to identify
factors predictive of midterm to long-term survival, as well
as functional outcome.1 The purpose of this article is to
extend the findings of these prior reports and specifically
identify predictors of short-term mortality and morbidity
after LVRS in the NETT population, including operative
Abbreviations and Acronyms
CT  computed tomography
DLCO  diffusing capacity for carbon monoxide
FEV1  forced expiratory volume in 1 second
HU  Hounsfield unit
LVRS lung volume reduction surgery
NETT National Emphysema Treatment Trial
QIA  quantitative image analysis
RO  relative odds
UCSD University of California San Diegomortality and major cardiopulmonary complications.
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Study Design
The designs and methods of the NETT have been fully described
in a prior publication but will be reviewed briefly.10 Patients with
severe emphysema underwent thorough medical evaluation to con-
firm the presence of severe emphysema and overall fitness for
potential LVRS candidacy. These evaluations were undertaken at
17 NETT clinical centers throughout the country that had been
selected by the National Heart, Lung, and Blood Institute. Baseline
measurements included collection of demographic data, postbron-
chodilator spirometry, lung volume plethysmographic assessment,
chest computed tomography (CT), split ventilation-perfusion nu-
clear imaging, standard anteroposterior and lateral chest radiogra-
phy, cardiovascular assessment (routine dobutamine stress tests
and echocardiography), and exercise capacity, as measured both
by means of a standardized 6-minute walk and formal maximum
symptom-limited cycle ergometry with graded exercise loading
and oxygen supplementation. In addition, patients underwent as-
sessment of their subjective well-being by using questionnaires
regarding dyspnea (University of California San Diego [UCSD]
Shortness of Breath Questionnaire and St George’s Respiratory
Questionnaire) and quality of life (Quality of Well Being scale and
SF-36 short form questionnaire).
Diagnostic Imaging Studies
The distribution of emphysema was determined by using several
methodologies. Initially, it was classified as heterogeneous or
homogeneous on the basis of the high-resolution CT scan by using
a visual scoring system in which the radiologist had been trained
and certified. The radiologist also classified the craniocaudal distri-
bution of emphysema as affecting predominantly the upper lobes
(upper-lobe-predominant disease), or it was reported as mainly in-
volving the lower lobes, the superior segment of the lower lobes, or
the lungs. These latter 3 classifications were grouped together under
the heading of non–upper-lobe emphysema. A complete description
of this evaluation technique has been previously published.10
Additionally, a measure of emphysema distribution was ob-
tained by using quantitative image analysis (QIA) of digitized
spiral CT scans. Patients screened between October 1997 and July
2002 were imaged by using various single-slice spiral CT scan-
ners. Patients were instructed to hold their breath at full inspiration
(at or near-total lung capacity). A volumetric image data set was
reconstructed, with slice thickness ranging between 5 and 10
mm (the majority of studies had a slice thickness of 7-8 mm)
and slice spacing set to half of the slice thickness. Image data
were reconstructed by using the appropriate scanner equivalent
of a normal reconstruction kernel. A software package devel-
oped by the University of Iowa (Pulmonary Analysis Software
Suite) was used to identify the lungs, divide the lungs into the
left and right lungs, and then divide each lung into the upper,
middle, and lower thirds on the basis of the apex-to-base
distance. The software also provided a set of metrics that
characterized the distribution of Hounsfield unit (HU) levels for
the voxels comprising each lung region, including the number
of voxels with density of less than 950 HU, a level generally
accepted as corresponding to severe emphysema. This count
was used with the total number of voxels comprising a region to
obtain the proportion of emphysema for the region expressed as
ry 2006
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TSa percentage. The difference between the upper lung and the
lower lung in the percentage of emphysema at the 950 HU
threshold was used to categorize the disease. Those whose
percentage of emphysema was greater in the upper than in the
lower cuts were classified as upper lobe predominant emphy-
sema and all others were non– upper-lobe-predominant
emphysema.
A second distribution metric was calculated by the software
on the basis of the number and size of holes in the lung, as
demonstrated in the digitized CT scans. This was designated as
the  measure and is based on the work of Mishima and
colleagues.11 They hypothesized that if the initial onset of
emphysema was a random process whereby small holes ap-
peared randomly throughout a lung region, the log-log plot of
the percentage of holes in that region versus hole size would
prove to be linear. Then if the progression of the disease is
based on the small holes destabilizing a region whereby small
holes join to form large holes, the slope of the log-log plot of
percentage holes (y-axis) versus hole size (x-axis) will decrease
as larger holes increasingly dominate over small holes and
provides a measure of emphysema severity. In our analysis a
hole in the lung is defined as voxels of less than 950 HU. The
slope from the log-log relationship of hole size plotted against
the number of “holes” determines the alpha value. The differ-
ence between the upper lung and the lower lung in alpha at the
–950 HU threshold determines site of predominance. When
alpha is less than 0 it is upper lobe predominant versus non–
upper lobe predominant when it is 0 or higher.
Finally, a measurement of the distribution was obtained from
nuclear imaging scans. The regional distribution was quantified,
and the ratio of upper-lobe perfusion to lower-lobe perfusion was
obtained.
All patients eligible for randomization were required to com-
plete a 6- to 10-week course of formal outpatient pulmonary
rehabilitation supervised by the clinical centers. After pulmonary
rehabilitation, repeat physiologic testing and patient assessment
was conducted before randomization to continued medical therapy
with maintenance rehabilitation or LVRS, followed by continued
medical treatment and maintenance rehabilitation.
Patients randomized to LVRS underwent a bilateral stapled
wedge resection with the goal of resecting 20% to 35% of each
lung. The resections were targeted by using the imaging modalities
of both CT scans and nuclear images of the lung. Eight centers
performed the operation by means of median sternotomy, 3 centers
by means of video-assisted thoracic surgery, and 6 centers by
means of median sternotomy or video-assisted thoracic surgery
selected randomly.
Definition of Outcome
Because of the prolonged duration of hospitalization in many
patients undergoing LVRS and the frequently observed discharge
from the acute-care hospital to a chronic-care facility, neither
30-day mortality nor hospital discharge mortality were believed to
be representative of the true risk of mortality. Thus the 90-day
mortality from all causes (measured from the day of LVRS) was
chosen as the best surrogate for overall operative mortality.
Vital status was determined by using routine reports from the
clinical centers, as well as from a review of the 2004 Death
The Journal of ThoracMaster File from the Social Security Administration. Major
pulmonary morbidity was defined as the need within 30 days of
the operation for tracheostomy, reintubation, or ventilator sup-
port for 3 or more days; pneumonia within 30 days of the
operation; or ventilator dependency for more than 30 days after
LVRS. Major cardiovascular morbidity was defined as intraop-
erative arrhythmia requiring pharmaceutical or electrophysi-
ologic treatment or myocardial infarction, pulmonary embolus,
or arrhythmia requiring treatment within 30 days after LVRS.
Statistical Analysis
Predictors for each of the 3 outcomes were investigated by
using univariate and multivariate logistic regression. The rela-
tive odds (RO) obtained from the logistic regression expresses
either the risk of the outcome for patients with the specified
factor compared with the risk for patients without the factor
(binary factor) or the incremental risk per each unit change in
the factor (continuous factor). Candidate predictors were 23
clinical variables describing demographics (age, sex, and race-
ethnicity), physical condition (body mass index; oxygen use at
rest, with exercise, and during sleep; prescription of oral ste-
roids at the postrehabilitation, prerandomization visit; and se-
rum creatinine level), pulmonary function measures (forced
expiratory volume in 1 second [FEV1] percent predicted, resid-
ual volume percent predicted, ratio of residual volume to total
lung capacity ratio, the diffusing capacity for carbon monoxide
[DLCO], PaCO2, and the ratio of expired volume to the volume of
CO2), exercise capacity (6-minute walk distance and maximum
exercise capacity by means of bicycle ergometry [categorized
as low or high]), dyspnea (UCSD Shortness of Breath Ques-
tionnaire and St George’s Respiratory Questionnaire scores)
and quality of life (Quality of Well-Being Scale), and imaging
measures (perfusion ratio and assessments by the study radiol-
ogists of heterogeneity, upper-lobe distribution, and hyperinfla-
tion), as well as by means of computerized analysis of CT scans
performed at the imaging center.
The NETT was approved by the institutional review boards at
each of the 17 clinical centers, and informed consent was obtained
from all participants.
Results
Between January 1998 and July 2002, 3777 patients were
considered for entry into the NETT, and 1218 progressed
through screening evaluation, formal pulmonary rehabili-
tation, repeat physiologic and radiologic testing, and
randomization to treatment. There were 610 patients as-
signed to medical therapy and 608 to surgical therapy. Of
the 608 patients randomized to surgical therapy, 580
(95.4%) eventually underwent LVRS either by using a
median sternotomy approach (406 patients) or by means
of video-assisted surgery (174 patients). Twenty-one pa-
tients randomized to LVRS declined surgical interven-
tion, and 7 patients were deemed unsuitable for surgical
intervention by the surgeon or anesthesiologist at some
point after randomization. Sixty-nine of the 580 patients
who underwent LVRS were in the subgroup identified by
ic and Cardiovascular Surgery ● Volume 131, Number 1 45
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risk of mortality after LVRS with little chance of func-
tional benefit; enrollment of this patient subgroup in the
NETT was terminated in May 2001. This high-risk pa-
tient subgroup has already been described in a previous
publication, and they are excluded from this analysis.12
The remaining 511 non– high-risk patients who under-
went LVRS are the subject of this report.
Patient Characteristics
Table 1 depicts baseline clinical characteristics. The ma-
jority of patients were men, and the average age at the
TABLE 1. Characteristics of patients at baseline* (n 511)
Characteristic Mean  SD or n (%)
Age at surgical intervention, y 67.0 6.2
Sex
Female 219 (42.9)
Male 292 (57.1)
Emphysema distribution on CT
Predominant upper lobe 332 (65.0)
Predominant non–upper lobe 179 (35.0)
Heterogeneous (%)† 295 (57.7)
Homogeneous (%)† 216 (42.3)
FEV1 after BD use, % predicted 28.1 6.8
TLC after BD use, % predicted 127.3 15.1
RV after BD use, % predicted 214.4 45.6
DLCO, % predicted 29.2 9.3
PaO2, mm Hg 65.2 10.6
PaCO2, mm Hg 42.8 5.6
Saint George’s Respiratory Questionnaire
total score‡
52.2 12.8
UCSD Shortness of Breath Questionnaire
total score§
61.0 18.4
Quality of Well-Being Scale average
daily score
0.58 0.12
SD, Standard deviation; CT, computed tomography; FEV1, forced expi-
ratory volume in 1 second; BD, bronchodilator; TLC, total lung capacity;
RV, residual volume; DLCO, diffusion capacity; PaO2, partial pressure of
arterial oxygen; Paco2, partial pressure of arterial carbon dioxide;
UCSD, University of California at San Diego. *Baseline measurements
are obtained after rehabilitation and before randomization, except for the
diffusion capacity of carbon dioxide, which is obtained before rehabilita-
tion and before randomization. †Emphysema distribution is based on
scores assigned subjectively to each of 3 lung zones in each lung. ‡The
Saint George’s Respiratory Questionnaire is a 51-item questionnaire com-
pleted by the patient with regard to respiratory symptoms, where the total
score ranges from 0 to 100, and lower scores indicate fewer respiratory
symptoms. §The UCSD Shortness of Breath Questionnaire is a 24-item
questionnaire completed by the patient with regard to shortness of breath,
where the total score ranges from 0 to 120, and lower scores indicate less
shortness of breath. The Quality of Well-Being Scale is a 77-item ques-
tionnaire completed by the patient with regard to quality of life. The
average daily total score ranges from 0 to 1, where higher scores indicate
better quality of life.time of the operation was 67 years. The distribution of
46 The Journal of Thoracic and Cardiovascular Surgery ● Januaemphysema was upper-lobe predominant in approxi-
mately two thirds of patients and judged as heteroge-
neous in 58% of patients. Mean FEV1 percent predicted
was 28%, and mean residual volume was 215% of pre-
dicted value. At baseline rest, patients were neither hy-
poxemic nor severely hypercapneic but did demonstrate a
severe degree of dyspnea, as shown by the St George’s
Respiratory Questionnaire and the UCSD Shortness of
Breath Questionnaire scores.
Operative Morbidity
Table 2 outlines the intraoperative and postoperative mor-
bidity. More than 90% of patients had no intraoperative
TABLE 2. Complications and mortality (n  511)
Intraoperative
None 91.0%
Hypotension 0.4%
Arrhythmia 1.2%
Arrhythmia requiring treatment 1.0%
Hypoxemia 2.2%
Cardiac arrest 0.4%
Uncontrolled air leak 1.0%
Postoperative (within 30 d of operation)
None 41.3%
Arrhythmia 23.5%
Arrhythmia requiring treatment 18.6%
Myocardial infarction 1.0%
Failure of early extubation 3.9%
Tracheostomy 8.2%
Failure to wean 5.1%
Reoperation for air leak 3.3%
Pulmonary embolus 0.8%
Readmission to ICU 11.7%
Mediastinitis 0.6%
Sternal debridement 0.6%
Pneumonia 18.2%
Urinary retention 3.5%
Epidural catheter complications 0.8%
Sepsis 2.5%
Readmission within 72 h after discharge 2.5%
Ventilated more than 2 d 13.6%
At least 1 reintubation 21.8%
Major pulmonary morbidity* 29.8%
Major cardiac morbidity† 20.0%
Dead within 90 d of operation 5.5%
ICU, Intensive care unit. *Major pulmonary morbidity is defined as inci-
dence of 1 or more of the following in the 30 days after lung volume
reduction surgery: tracheostomy, failure to wean, pneumonia, at least 1
postoperative intubation, or ventilator use for 3 or more days. †Major
cardiac morbidity is defined as incidence of 1 or more of the following:
intraoperative or postoperative (in the 30 days after lung volume reduction
surgery) arrhythmia requiring treatment or myocardial infarction or pulmo-
nary embolus in the 30 days after lung volume reduction surgery.complications; however, more than 50% of patients had
ry 2006
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2, the most frequent complication was the need for reintu-
bation (22%), followed by postoperative arrhythmia requir-
ing therapy (19%), pneumonia (18%), mechanical ventila-
tion for 3 or more days (14%), and the need for a
tracheostomy (8%). Of note, almost 12% of patients re-
quired readmission to the intensive care unit at some time
during the initial hospitalization. The incidence of major
pulmonary morbidity was almost 30%, and the incidence of
TABLE 3. Factors related to death 90 or fewer days after
%
Risk factor
No. of patients
Demographics
Age at operation, y (per y of age)
Minority (yes vs no)
Male sex (yes vs no)
Treatment and physical condition
Body mass index, kg/m2 (per unit change)
Using oxygen constantly (yes vs no)
Prescribed oral steroids at baseline (yes vs no)
Abnormal creatinine level at baseline (yes vs no)
Radiologic measures
Nonheterogeneous (radiologist evaluation; yes vs no)
Non–upper lobe (radiologist evaluation; yes vs no)
Hyperinflation on chest radiograph (any vs none)
Perfusion ratio (per unit change)
Non–upper lobe, QIA  measure (n  458; yes vs no)
Non–upper lobe, QIA % emphysema measure (n  458;
yes vs no)
Pulmonary function measures
FEV1 percent predicted (per unit change)
RV percent predicted (per unit change)
RV/TLC (per unit change)
DLCO percent predicted (per unit change)
PaCO2 (per mm Hg)
Exercise measures
Low exercise (yes vs no)
Ve/VCO2 at max work (per unit change)
Six-min walk distance (per ft)
QOL measures
UCSD SOB total score (per unit change)
QWB average daily score (per unit change)
RO, Relative odds; QIA, quantitative image analysis; FEV1, forced expira
diffusion capacity; PaCO2, partial pressure of arterial carbon dioxide; Ve
of life; UCSD SOB, University of California at San Diego Shortness of
defined as the ratio of the odds for those with versus the odds for those w
the factor (continuous). †Wald 2 test for logistic regression with response
of risk factor. ‡P value for stepwise logistic regression (forward selection)
(yes vs no) and candidate regressors of all factors listed in the table. §nmajor cardiac morbidity was 20%.
The Journal of ThoracOperative (90-day) Mortality
The 90-day mortality after LVRS was 5.5% (28 patients,
Table 2) among the 511 non–high-risk patients. The stated
cause of death was respiratory (pneumonia, acute respira-
tory distress syndrome, aspiration, and progressive respira-
tory failure) in 12 (43%) patients, cardiovascular (infarc-
tion, arrhythmia, and pulmonary embolism) in 5 (18%)
patients, multiorgan failure in 2 (7%) patients, cerebrovas-
cular accident and sepsis in 1 (4%) patient each, and un-
volume reduction surgery
Logistic regression relative odds of death
within 90 days*
risk factor
r mean
Unadjusted
Final model after
backward selection
RO P value† RO P value‡
11 425§
67.0 1.07 .06 — —
4.7% 0.74 .77 — —
57.1% 1.62 .24 — —
24.7 0.94 .25 — —
49.1% 1.41 .38 — —
31.9% 0.85 .70 — —
10.6% 1.02 .98 — —
42.3% 1.20 .65 — —
35.0% 3.06 .005 2.99 .009
96.6% 0.94 .95 — —
0.30 2.31 .23 — —
47.4% 2.63 .03 — —
22.1% 1.32 .54 — —
28.1 1.00 .90 — —
14.4 1.00 .74 — —
0.64 0.04 .19 — —
29.2 0.97 .21 — —
42.8 0.97 .46 — —
40.9% 0.93 .86 — —
0.37 6.79 .33 — —
46 1.00 .53 — —
61.0 1.00 .79 — —
0.58 2.71 .55 — —
olume in 1 second; RV, residual volume; TLC, total lung capacity; DLCO,
, ratio of expired volume to the volume of carbon dioxide; QOL, quality
th Questionnaire; QWB, Quality of Well-Being Scale. *Relative odds is
t the factor (yes vs no) or incremental odds for each specified change in
ble of death within 90 days of lung volume reduction surgery and regressor
esponse variable of death within 90 days of lung volume reduction surgery
1 because of missing data and ability to estimate.lung
with
o
5
2
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/VCO2
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for operative mortality, including age at the time of the
operation (P  .06), non–upper-lobe-predominant emphy-
sema determined by the radiologist (P  .005), and non–
upper-lobe emphysema determined by using the  measure
with quantitative CT image analysis (P  .03). The logistic
regression model with backward selection determined that a
single factor, non–upper-lobe-predominant emphysema de-
termined by the radiologist, was predictive of 90-day mor-
TABLE 4. Factors related to major pulmonary morbidity in
Risk factor
No. of patients
Demographics
Age at operation, y (per y of age)
Minority (yes vs no)
Male sex (yes vs no)
Treatment and physical condition
Body mass index, kg/m2 (per unit change)
Using oxygen constantly (yes vs no)
Prescribed oral steroids at baseline (yes vs no)
Abnormal creatinine level at baseline (yes vs no)
Radiologic measures
Nonheterogeneous (radiologist evaluation; yes vs no)
Non–upper lobe (radiologist evaluation; yes vs no)
Hyperinflation on chest radiograph (any vs none)
Perfusion ratio (per unit change)
Non–upper lobe, QIA  measure (n  458; yes vs no)
Non–upper lobe, QIA % emphysema measure (n  458; yes vs
Pulmonary function measures
FEV1 percent predicted (per unit change)
RV percent predicted (per unit change)
RV/TLC (per unit change)
DLCO percent predicted (per unit change)
PaCO2 (per mm Hg)
Exercise measures
Low exercise (yes vs no)
Ve/VCO2 (per unit change)
Six-min walk distance (per ft)
QOL measures
UCSD SOB total score (per unit change)
QWB average daily score (per unit change)
RO, Relative odds; QIA, quantitative image analysis; FEV1, forced expira
diffusion capacity; PaCO2, partial pressure of arterial carbon dioxide; Ve
of life; UCSD SOB, University of California at San Diego Shortness of B
morbidity is defined as incidence of 1 or more of the following in the 30 days
at least 1 postoperative intubation, or ventilator use for 3 or more days. †R
for those without the factor (yes vs no) or incremental odds for each speci
response variable of major pulmonary morbidity in the 30 days after lung
stepwise logistic regression (forward selection) with response variable of
and candidate regressors of all factors listed in the table. n  511 becatality (RO, 2.99; P  .009).
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The univariate analysis suggested several factors potentially
predictive for major pulmonary morbidity in the first 30
days after LVRS (Table 4). These included age at the time
of the operation (P  .08), continuous oxygen use (P 
.05), FEV1 percent predicted (P  .03), DLCO percent
predicted (P  .003), and low exercise capacity, as
measured by means of symptom-limited maximum cycle
ergometry (P  .02). However, the logistic regression
30 days after lung volume reduction surgery*
Logistic regression relative odds of
pulmonary morbidity in 30 d†
% with risk factor or
mean
Unadjusted
Final model after
backward selection
RO P value‡ RO P value§
511 440
67.0 1.03 .08 1.05 .02
4.7% 0.78 .60 — —
57.1% 1.22 .32 — —
24.7 0.97 .32 — —
49.1 1.48 .05 — —
31.9% 0.94 .76 — —
10.6% 1.21 .54 — —
42.3% 0.95 .81 — —
35.0% 1.12 .58 — —
96.6% 1.02 .97 — —
0.30 1.05 .91 — —
47.4% 1.09 .68 — —
22.1% 0.92 .74 — —
28.1 0.97 .03 0.97 .05
214.4 1.00 .55 — —
0.64 2.49 .45 — —
29.2 0.97 .003 0.97 .01
42.8 1.00 .79 — —
40.9% 1.57 .02 — —
0.37 2.40 0.42 — —
1246 1.00 .10 — —
61.0 1.01 .22 — —
0.58 0.36 .23 — —
olume in 1 second; RV, residual volume; TLC, total lung capacity; DLCO,
, ratio of expired volume to the volume of carbon dioxide; QOL, quality
h Questionnaire; QWB, Quality of Well-Being Scale. *Major pulmonary
lung volume reduction surgery: tracheostomy, failure to wean, pneumonia,
e odds is defined as the ratio of the odds for those with versus the odds
hange in the factor (continuous). ‡Wald 2 test for logistic regression with
e reduction surgery (yes vs no) and regressor of risk factor. §P value for
r pulmonary morbidity in the 30 days after lung volume reduction surgery
f missing data.the
no)
tory v
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reat
after
elativ
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majomodel determined that only 3 of these factors were in-
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These included age (RO, 1.05; P  .02), FEV1 percent
predicted (RO, 0.97; P  .05), and DLCO percent pre-
dicted (RO, 0.97; P  .01).
Major Cardiac Morbidity
Table 5 shows the analysis for predictors of major cardiac
morbidity. The univariate analysis suggests that as many as
6 factors might be predictive for major cardiac morbidity.
TABLE 5. Factors related to major cardiac morbidity in th
Risk factor
No. of patients
Demographics
Age at operation, y (per y of age)
Minority (yes vs no)
Male sex (yes vs no)
Treatment and physical condition
Body mass index, kg/m2 (per unit change)
Using oxygen constantly (yes vs no)
Prescribed oral steroids at baseline (yes vs no)
Abnormal creatinine level at baseline (yes vs no)
Radiologic measures
Nonheterogeneous (radiologist evaluation; yes vs no)
Non–upper lobe (radiologist evaluation; yes vs no)
Hyperinflation on chest radiograph (any vs none)
Perfusion ratio (per unit change)
Non–upper lobe, QIA  measure (n  458; yes vs no)
Non–upper lobe, QIA % emphysema measure (n  458; yes vs
Pulmonary function measures
FEV1 percent predicted (per unit change)
RV percent predicted (per unit change)
RV/TLC
DLCO percent predicted (per unit change)
PaCO2 (per mm Hg)
Exercise measures
Low exercise (yes vs no)
Ve/VCO2 (per unit change)
Six-min walk distance (per ft)
QOL measures
UCSD SOB total score (per unit change)
QWB average daily score (per unit change)
RO, Relative odds; QIA, quantitative image analysis; FEV1, forced expiratory
capacity; PaCO2, partial pressure of arterial carbon dioxide; Ve/VCO2, ratio of
UCSD Shortness of Breath Questionnaire; QWB, Quality of Well-Being Scal
intraoperative or postoperative (in the 30 days after lung volume reduction
embolus in the 30 days after lung volume reduction surgery. †Relative od
without the factor (yes vs no) or incremental odds for each specified chang
variable of major cardiac morbidity in the 30 days after lung volume reducti
regression (forward selection) with response variable of major cardiac
regressors of all factors listed in the table. n  511 because of missingThese include age at the time of the operation (P  .001),
The Journal of Thoracmale sex (P  .01), perfusion ratio (P  .09), non–upper-
lobe-predominant emphysema determined from the  mea-
sure from the quantitative CT image analysis (P  .001),
PaCO2 (P  .09), and low exercise capacity (P  .04).
However, the multivariate logistic regression determined
only 3 factors proved to be independent predictors, and
these included age at the time of the operation (RO, 1.07;
P  .004), oral steroid use at the time of the operation (RO,
days after lung volume reduction surgery*
Logistic regression relative odds of cardiac
morbidity in 30 days†
% with risk factor
or mean
Unadjusted
Final model after
backward selection
RO P value‡ RO P value§
511 440
67.0 1.07 .001 1.07 .004
4.7% 0.56 .36 — —
57.1% 1.84 .01 — —
24.7 0.99 .82 — —
49.1 1.27 .28 — —
31.9% 1.35 .20 1.72 .04
10.6% 1.64 .13 — —
42.3% 1.21 .39 — —
35.0% 1.32 .22 — —
96.6% 0.44 .12 — —
0.30 2.21 .09 — —
47.4% 2.65 .001 2.67 .001
22.1% 1.53 .11 — —
28.1 0.99 .53 — —
214.4 1.00 .84 — —
0.64 0.73 .82 — —
29.2 1.00 .84 — —
42.8 1.03 .09 — —
40.9% 1.59 .04 — —
0.37 1.51 .74 — —
1246 1.00 .12 — —
61.0 0.99 .22 — —
0.58 1.19 .86 — —
e in 1 second; RV, residual volume; TLC, total lung capacity; DLCO, diffusion
ed volume to the volume of carbon dioxide; QOL, quality of life; UCSD SOB,
ajor cardiac morbidity is defined as incidence of 1 or more of the following:
ery) arrhythmia requiring treatment or myocardial infarction or pulmonary
defined as the ratio of the odds for those with versus the odds for those
he factor (continuous). ‡Wald 2 test for logistic regression with response
gery (yes vs no) and regressor of risk factor. §P value for stepwise logistic
idity in the 30 days after lung volume reduction surgery and candidatee 30
no)
volum
expir
e. *M
surg
ds is
e in t
on sur
morb1.72; P  .04), and non–upper-lobe-predominant emphy-
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image analysis (RO, 2.67; P  .001).
Discussion
Reported predictors of short-term mortality, operative mor-
tality, or both after LVRS have included many factors
describing patient demographic profile, spirometry, lung
volume, gas exchange, exercise tolerance, and imaging
studies (Table 6).4-8,10,13-17 Unfortunately, the predictive
risk factors vary widely from article to article, and their
validity is questionable. In several reports age is described
as a strong predictor of morbidity6,8 yet is reported to be
insignificant in others.4,5,13 Similarly, PaCO2 was noted as a
significant risk factor by some investigators4,14,16 but not by
others.6,13,15 Likely some of this uncertainty is due to the
very nature of the studies cited. They were, in general,
single-institution, nonrandomized, uncontrolled trials that
involved small numbers of patients with variable measures
and time points for evaluation, as well as a lack of consis-
tency in the manner in which testing was conducted. Selec-
tion criteria varied from institution to institution, and the
operative techniques varied widely as well.
The lack of consistency between these reports made risk
assessment quite problematic for physicians counseling pa-
tients regarding the risks and benefits of LVRS. However,
many of the above shortcomings were addressed with the
institution of the NETT, a prospective, multi-institutional,
randomized controlled trial that eventually enrolled more
TABLE 6. Predictors of mortality in prior publications
Age Naunheim and coworkers6
Glaspole and coworkers8
Male sex Naunheim and coworkers6
Ciccone and coworkers13
Exercise tolerance Szekely and coworkers4
Naunheim and coworkers6
Geddes and coworkers7
Ciccone and coworkers13
PaCO2 Szekely and coworkers
4
O’Brien and coworkers14
Keenan and coworkers5
FEV1 NETT
10
Ciccone and coworkers13
DLCO Geddes and coworkers7
Keenan and coworkers5
NETT10
Imaging studies Slone and coworkers16
Wisser and coworkers15
NETT10
Weder and coworkers17
PaCO2, Partial pressure of arterial carbon dioxide; FEV1, forced expiratory
volume in 1 second; NETT, National Emphysema Treatment Trial; DLCO,
diffusion capacity.than 1200 patients. One of the major secondary end points
50 The Journal of Thoracic and Cardiovascular Surgery ● Januain the NETT was to provide clinical insight to allow for
optimal patient selection, both with regard to risk and out-
come. The NETT protocol was carefully designed to com-
prehensively characterize patients’ preoperative pulmonary,
cardiac, and functional status to diminish the effect of
underlying significant diseases that would adversely affect
patient outcome. Therefore the complications that we report
in this study are ones that occurred in the setting of patients
who had no overt signs of existing cardiopulmonary disease
before LVRS other than their emphysema.
The first clinical publication of the NETT fulfilled this
goal partially when it identified a subgroup of patients at
exceedingly high risk for operative mortality and poor out-
come measured at 6 months.11 Those patients with an FEV1
of less than 20% of predicted value and either a DLCO of less
than 20% of predicted value or homogeneous distribution of
emphysema as assessed by the radiologist were found to
have a high 30-day mortality (16%) without substantially
improved functional outcome in survivors compared with
that seen in the medically treated control group at 6 months
after randomization to treatment. Once this high-risk sub-
group was identified, such patients were excluded from
further entry into the trial; however, accrual of non–high-
risk patients continued. A subsequent NETT publication has
identified predictors of outcome and survival after an aver-
age of 29 months of follow-up; however, an analysis re-
garding early surgical mortality and morbidity has been
lacking up to the present time.1
Significant cardiac morbidity has been rarely reported
with LVRS, with the exception of the development of
arrhythmias, including atrial fibrillation, supraventricular
tachycardia, and some ventricular arrhythmias. The only
independent predictors for cardiac morbidity were increas-
ing age, oral steroid use, and non–upper-lobe-predominant
emphysema identified by the  measure on QIA. It is
doubtful whether preoperative identification of these factors
would likely be of great benefit in avoiding cardiac mor-
bidity. The QIA model is not widely available, and the
effect of increasing age, although significant, is so small it
is unlikely to be of great clinical value. Perhaps clinically,
the most practical suggestion would be to consider prophy-
lactic pharmacologic prevention, as is currently undertaken
in many cardiac surgery practices. Indeed, the incidence of
these arrhythmias approaches that found after routine cor-
onary artery bypass surgery, and prophylaxis might prove to
be the best strategy. However, because this strategy was not
studied, its value is purely speculative.
Pulmonary morbidity is perhaps the most daunting as-
pect of perioperative care for patients undergoing LVRS.
Approximately 5% of patients fall into the failure to wean
category, 18% had pneumonia, and 8% eventually proceed
to tracheostomy, whereas more than 7% of patients will
spend more than 2 weeks on the ventilator. Once again,
ry 2006
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significant pulmonary morbidity will likely prove futile.
Although age, FEV1 percent predicted, and DLCO are all
statistically predictive of increased pulmonary morbidity,
the changes in the RO ratio are not great, and it is highly
unlikely any specific threshold could be identified that
would represent a valid cutoff for patients or physicians.
Perhaps patients with 2 or more risk factors (age 70 years
and either FEV1 or DLCO approaching 20% of predicted
value) should be seen as approaching the previously pub-
lished high-risk cohort and could be reasonably counseled
against LVRS.
Perhaps the only area in which this risk analysis model is
likely to be helpful clinically is in the arena of operative
mortality. non–upper-lobe-predominant emphysema deter-
mined by the radiologist had an RO ratio of 2.99 (P .009),
suggesting that even in this non–high-risk group, patients
with non–upper—lobe-predominant emphysema carry a
significantly increased risk of dying within the first 90 days
after LVRS. This factor has already been shown to be
predictive of both poor physiologic outcome and worse
operative mortality in a cohort of patients with preserved
exercise capacity.1,12 The current findings emphasize the
point that the distribution of emphysema identified on the
chest CT might be useful in guiding the physician in coun-
seling the patient regarding the advisability of this proce-
dure. A practitioner considering LVRS must think long and
hard before suggesting this surgical intervention for patients
who have been demonstrated as having non–upper-lobe-
predominant emphysema, even if all other factors appear
encouraging. Although it is impossible to predict results in
any individual patient, the combination of relatively in-
creased operative mortality coupled with the inferior outcomes
already described makes the decision for surgical intervention
in this particular patient subgroup highly suspect.
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Discussion
Dr Joel D. Cooper (St Louis, Mo). Thank you for the opportunity,
and thank you, Dr. Naunheim, for an excellent presentation and a
chance to review the article. It is widely overlooked that the
National Emphysema Treatment Trial (NETT) trial did have in
advance a written hypothesis. The hypothesis stated “that patients
who improve will have preoperative heterogeneously distributed
emphysema involving the upper lobes predominantly.” One of the
disappointments of the NETT trial was the unwillingness to pro-
spectively stratify patients according to that hypothesis to allow
prospective analysis, and one of the major criticisms has been that
most analyses now have had to be post hoc subgroup analyses,
which detracts from the strength of the conclusions. To date, none
of the NETT publications, including the presentation today, have
stratified the patients according to the hypothesis of the trial, and
therefore one question I have is this: When will the database be
available so that the analysis of the group who are hypothesized to
be lowest risk and greatest benefit will be available?
Our own single-institution population of about 300 patients is
clearly a different set of patients: they have only heterogeneous
distribution, with 92% of them having upper-lobe-predominant
emphysema. I believe that is the reason why there is a disparity
between the results we and others have obtained and those reported
by the NETT, specifically reintubation in our series of 7% versus
22%, tracheostomy in our series of 4% versus 8%, and overall
pulmonary morbidity of 14% instead of 30%. I think this has
nothing to do with the skill or the care of the patients. I think it has
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second question is that I would like to ask your opinion of that.
I have always been a bit confused by the difference between
homogenous distribution of emphysema and non– upper-lobe-
predominant emphysema. In the figures that you presented, 67%
of patients were classified as having the upper-lobe-predominant
pattern, but only 58% of all the patients were described as having
a heterogeneous pattern. This means that many of the patients
classified as having upper-lobe-predominant emphysema were also
classified as homogenous rather than heterogeneous, and I wonder
if you could help me understand that.
Your mortality risk showed that, by far, the greatest factor was
non–upper-lobe-predominant emphysema (an odds ratio of 3).
Have you any idea why this predictor did not hold up for your
major pulmonary morbidity? Pulmonary morbidity was the major
cause of death. You showed that mortality was related to it but not
morbidity in terms of the distribution of the emphysema pattern.
Finally, previous NETT publications have identified exercise
capacity as an important prognostic indicator to the point that some
Medicare patients are now denied the operation on the basis of that
discriminator. Do you have any idea why that discriminator, ex-
ercise capacity, did not fall out as a major predictor of morbidity
and mortality in your analysis?
Thank you very much for the privilege.
Dr Naunheim. Thank you, Joel. The answer to your first
question is that the database will be available to the public in the
spring of 2006.
The premise of the NETT trial was to do a prospective ran-
domized trial comparing medical versus surgical therapy for a
wide variety of patients and not just those with upper-lobe heter-
ogeneous disease. There is no doubt that the inclusion criteria
within the NETT trial were broader and intentionally so than those
used by Dr Cooper and some other investigators. The idea was not
just to determine whether the procedure was going to be effective
but also in what group of patients it would be effective or inef-
fective and contraindicated. Thus it is true that our patient popu-
lation is more diverse than that of Dr Cooper and his colleagues
and than those of other investigators in the field.
The disparity between results with regard to the incidence ofThe Journal of Thoracto this difference in patient selection. First of all, our patients,
because of the Medicare funding, were on average 5 years older
than in other series, and as you know, in this ill patient subset 5
years is an eternity. Therefore our patients were indeed older, more
ill, and more fragile and did have more homogenous disease.
The question of upper-lobe versus heterogeneous disease is one
we have also asked. You said that 67% of the patients were
classified as having upper-lobe-predominant emphysema and only
58% as heterogeneous, and that really has to do with the subjective
radiologist’s evaluation of the heterogeneity and of the predomi-
nance. This was purely subjective. We are hoping that eventually
the computerized analysis will give us a better and more objective
feel for who has upper-lobe predominance versus lower-lobe pre-
dominance and who has homogenous versus heterogeneous, but
that full analysis has not been done yet.
The fourth question was why upper-lobe emphysema did not
hold up for pulmonary morbidity, and that I honestly cannot
answer. I would have thought that it would have because it seemed
to be so consistent in both our first and second major publications,
in which homogeneity proved to be critical. Therefore the fact that
the distribution of emphysema was not significant as a predictor
for pulmonary morbidity also is a nettlesome question for us. I do
not have the answer for that.
Finally, why didn’t exercise capacity hold up as a predictor? If
you remember, the exercise capacity was reported in the midterm
survival and functional outcome results in the primary NETT
outcome trial paper. And the reason that exercise capacity ap-
peared to be a significant predictor was not because the surgical
patients mattered with regard to high or low exercise but more of
the fact that the medical patients who had low exercise capaci-
ty—as you remember, that was the indicator for “good out-
come”—those who had low exercise capacity in the medical group
deteriorated and died so quickly that it made the surgical group
look better by comparison. It had nothing to do with the surgical
group itself in regard to exercise capacity but rather with the very
fragile condition of the medical group who had poor exercise
capacity, and that group deteriorated very rapidly and died at an
increased rate. Therefore we did see exercise capacity as a predic-
tor of outcome and survival but only in the long term and not in thetracheostomy, reintubation, pneumonia, and the like is indeed due short term.
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